Doug Baker
Analyst · Tim Mulrooney with William Blair
Thanks, Mike, and good day to everybody. So, I'll just offer some comments on Q1 and a bit of perspective on 2020. So, our Q1 adjusted EPS results were better than expected, as we realized expected business acceleration versus Q4, the COVID-19 impacts were different than we anticipated. COVID-19 did negatively impact sales but also drove lower expense in T&E, benefits and other costs, which more than offset the sales impact. But this is not a pattern we see going forward. We know the coming COVID-19 period will be more adverse. But importantly, we entered this period in a position of strength. The business and company are in very good shape. We've got a great, very experienced team that's been through crisis before. We've got a resilient business model that generates cash regularly, and we have a strong balance sheet and cash reserves. So all of this is important as we expect the COVID-19 period to extend into 2021, and we believe the recovery will be shaped more like a U than a V. Finally, we also believe that COVID will have a significant impact on our business, short term, quite negative, but longer term, quite positive. So our guiding principle is really manage the short term in a way that positions us for maximum long-term benefit. That's where the value is. So, we've already taken a number of steps to do this. We created a cash reserve backstop. We cut expenses. We put in hiring freezes, eliminated merit increases, et cetera. We've also cut capital by 50% versus our budget, but preserved digital antimicrobial and hygiene tech investments as they were. Now, these are detailed examples of steps we've taken and how our approach of managing the year to maximize our post COVID potential shows up. But let me offer some perspective on the year in the future. So first, 2020. Like it seems everything is with COVID, the outcomes are going to be asymmetrical. We have businesses having record years or that we expect to have record years like F&B, Food Retail, Healthcare and Life Sciences. But we also have businesses competing in markets that have been virtually shut down, like Institutional, with restaurants, hotels, cruise lines, et cetera, really not in business in a material way. So, in total, the net impact of the pluses and minuses of these groups of businesses will be negative for the year on both top and bottom line, and we've signaled that previously. The timing impact over the course of the year, though, is going to be imbalanced, too. Q2, we believe, is going to be the most impacted quarter as we realize both the full effects of COVID-19 volume declines, driven by these temporary closures in key markets. Plus, we're also going to be realizing channel destocking at the same time. However, we expect Q3 and Q4 to start showing sequential recovery from Q2. This recovery during the second half will be driven certainly in part by reopenings, but also by expected increased demand for hygiene programs. Now, we're already seeing this across industries like F&B, Food Retail and even in traditional industrial settings, where we hadn't had this type of demand before. The recovery will be further driven by a number of our own initiatives that we already have underway. Look, we're feeding and fueling segments with momentum, F&B, FRS, Healthcare and Life Sciences. We're adding people, investing in capital, doing all the things that we need to do to build on that momentum. We're launching new offerings, particularly in hand care and sanitizer categories. And we're developing new applications for a powerful Bioquell system. Three, we're maintaining growth investments in animal health and data centers, which we have seen as great growth opportunities before COVID, and they remain great growth opportunities. And finally, we're actively pursuing new strategic customers. This is a great time to continue to talk about the benefits that we bring in good and difficult times. Now all of this represents what we call the early-stage development for the world after COVID. Our business will certainly be pressured this year, but we'll continue to generate positive cash flow and gain share throughout the year. We believe our clear leadership in hygiene, antimicrobial, digital, lowest use cost delivery; environmental offerings will be even more valued after the pandemic has passed. And a number of important factors we believe will remain true. We will still chase a huge market. We will still have a sizable competitive advantage. One might argue that our competitive advantage will be improved. We're in better shape than most of our competitors to handle a situation like this. We will have great customer relationships as we demonstrate we're the right partner, particularly when the going gets tough, then we will have answers for water scarcity, which will still be a huge issue. And finally, our ESG advantages will remain significant and important. But we also believe that, there's going to be new transformational opportunities as customers and communities' expectations evolve. And this is where we will put extraordinary time and effort as we move through this year. We see building an even broader and more robust set of annuity businesses as the highest priority for the year. This is what we've got to use this time to do. It's why we so firmly believe that managing through the short term in a way that positions us for maximum long-term benefit is the right play. So with that, I'll hand it back to Mike.